DAC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
== Drug design == In drug design, drug candidates may have good druglikeness but fail on first-pass metabolism because it is biochemically selective. Physiologically based pharmacokinetic models (PBPK) are used to predict first-pass metabolism, although they require compound-specific adjustments due to variability in intestinal mucosal permeability and other factors. Enzyme expression also varies between individuals, which may influence the efficiency of first-pass metabolism and thus the bioavailability of the drug. Cytochromes P450, especially CYP3A4, play a crucial role in first-pass metabolism, affecting the bioavailability of drugs.
Insulin-induced hypoglycemia Insulin injected for diabetes Factitious insulin injection (Munchausen syndrome) Excessive effects of oral Anti-diabetic medication, beta-blockers, or drug interactions Insulin-secreting neuroendocrine tumor (insulinoma) of the pancreas Alcohol induced hypoglycemia often linked with ketoacidosis (depletion of NAD+ leads to a block of gluconeogenesis) Alimentary (rapid jejunal emptying with exaggerated insulin response) After gastrectomy dumping syndrome or bowel bypass surgery or resection Reactive hypoglycemia and Idiopathic postprandial syndrome Tumor hypoglycemia, Doege-Potter syndrome Acquired adrenal insufficiency Acquired hypopituitarism Immunopathologic hypoglycemia
Lemelson-MIT Prize (2014) – known as the "Oscar for inventors", for groundbreaking inventions and dedication to the next generation of scientists. Heinz Award for Technology (2015) – for groundbreaking inventions and advocacy for women in STEM fields. Othmer Gold Medal (2019) – from the Science History Institute. Several honorary doctorate degrees, including from the Icahn School of Medicine at Mount Sinai (2021), University of London Institute Cancer Research (2019), and Utrecht University in the Netherlands (2017). Bhatia has also been honored with:
Sources: en.wikipedia.org
Dale, and A. Heath. Although Trooper Cochrane's letter made no mention of the fact, three Native South African witnesses were also shot dead. The ambush and fatal shooting of the Reverend Carl August Daniel Heese of the Berlin Missionary Society near Bandolierkop on the afternoon of 23 August. Rev. Heese had spiritually counseled the Dutch and Afrikaner victims that morning and angrily protested to Morant at Fort Edward upon learning of their deaths. Trooper Cochrane alleged that the killer of Heese was BVC Lt. Handcock. Although Cochrane made no mention that Heese's driver, a member of the Southern Ndebele people, was also killed. The orders, given by BVC Lt. Charles H.G. Hannam, to open fire on a wagon train containing Afrikaner women and children who were coming in to surrender at Fort Edward, on 5 September. The ensuing gunfire led to the deaths of two boys, aged 5 and 13, and the wounding of a 9-year-old girl. The shooting of Roelf van Staden and his sons Roelf and Christiaan, near Fort Edward on 7 September. All were coming to surrender in the hope of gaining medical treatment for Christiaan, who was suffering from fever. Instead, they were met at the Sweetwaters Farm near Fort Edward by a party consisting of Lts. Morant and Handcock, joined by BVC Sgt. Maj. Hammet, Corp. MacMahon, and Troopers Hodds, Botha, and Thompson. Roelf van Staden and both his sons were shot, allegedly after being forced to dig their graves. The letter then accused Field Commander of the BVC, Major Robert William Lenehan, of being "privy to these misdeamenours.
== Implementation == A simple representation can be made by defining two oppositely charged polyions as + and -, and defining the wash step as W. To make an LbL film with 5 bilayers one would deposit W+W-W+W-W+W-W+W-W+W-W, which would lead to a film with 5 bilayers, specifically + - + - + - + - + - . The representation of the LbL technique as a multilayer build-up based solely on electrostatic attraction is a simplification. Other interactions are involved in this process, including hydrophobic attraction. Multilayer build-up is enabled by multiple attractive forces acting cooperatively, typical for high-molecular weight building blocks, while electrostatic repulsion provides self-limitation of the absorption of individual layers. This range of interactions makes it possible to extend the LbL technique to hydrogen-bonded films, nanoparticles, similarly charged polymers, hydrophobic solvents, and other unusual systems. The bilayers and wash steps can be performed in many different ways including dip coating, spin-coating, spray-coating, flow based techniques and electro-magnetic techniques. The preparation method distinctly impacts the properties of the resultant films, allowing various applications to be realized. For example, a whole car has been coated with spray assembly, optically transparent films have been prepared with spin assembly, etc. Characterization of LbL film deposition is typically done by optical techniques such as dual polarisation interferometry or ellipsometry or mechanical techniques such as quartz crystal microbalance.
=== Dermal filler === In 2006, the US Food and Drug Administration approved an injectable dermal filler form of calcium hydroxyapatite (Radiesse) for the correction of moderate-to-severe facial folds, such as nasolabial folds, and for the restoration of volume in cases of HIV-associated facial lipoatrophy. The formulation typically consists of synthetic, smooth calcium hydroxyapatite microspheres (20–45 μm in diameter) suspended in a carboxymethylcellulose carrier gel. Upon injection in the skin, the gel provides immediate mechanical volumization, while the microspheres function as a scaffold for the endogenous production of collagen, elastin, and proteoglycans. This process is reported to lead to increases in skin thickness and structural elasticity. Clinical applications include jawline augmentation, hand rejuvenation, and the treatment of midface volume loss. Calcium hydroxyapatite is biodegradable, with the microspheres eventually undergoing macrophage-mediated phagocytosis and metabolic clearance over a period of approximately 12 to 30 months.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.